Format: BriefCase

1-6 of 6 Activities
Title
Availability
Format
Credits
Launch Date
Buttons
On-Demand
BriefCase
0.5
07/02/2025

Maintaining Patient QoL through Optimal Management of ADC-Associated AEs

In the third of this 3-part CEC Oncology BriefCase series, expert faculty and a patient advocate delve into interprofessional strategies for preventing and mitigating adverse events while collaboratively promoting QoL for patients being treated for HER2-negative MBC.

0.5
07/02/2025

Jennifer McKenna, RN, MSN, AOCNP

Jennifer McKenna, RN, MSN, AOCNP

Michelle Anderson-Benjamin, MHA

Michelle Anderson-Benjamin, MHA

Rita Nanda, MD, FASCO

Rita Nanda, MD, FASCO

Moderator

On-Demand
BriefCase
0.5
07/02/2025

Clinical Trial Data with ADCs: New Options for HER2-Negative MBC

In the second of this 3-part CEC Oncology BriefCase series, expert faculty review emerging data on ADC therapy for HER2-negative MBC, describe therapy selection and treatment sequencing rationale, and hear from a patient advocate about patient concerns regarding this new therapy option.

0.5
07/02/2025

Reshma L. Mahtani, DO

Reshma L. Mahtani, DO

Michelle Anderson-Benjamin, MHA

Michelle Anderson-Benjamin, MHA

Rita Nanda, MD, FASCO

Rita Nanda, MD, FASCO

Moderator

On-Demand
BriefCase
0.5
06/26/2025

ADCs and Chemotherapy: More Different Than You Might Expect in HER2-Negative MBC

In the first of this 3-part CEC Oncology BriefCase series, expert faculty introduce clinicians to ADC therapy for HER2-negative MBC and hear from a patient advocate about patient concerns regarding this new therapy option.

0.5
06/26/2025

Danielle Roman, PharmD, BCOP

Danielle Roman, PharmD, BCOP

Michelle Anderson-Benjamin, MHA

Michelle Anderson-Benjamin, MHA

Rita Nanda, MD, FASCO

Rita Nanda, MD, FASCO

Moderator

On-Demand
BriefCase
0.5
07/25/2024

ADCs in HR+/HER2- mBC: Managing AEs

The third episode of this CEC BriefCase series continues to follow the same patient case and explores how to use shared decision making (SDM) to design strategies to monitor for and manage AEs in patients receiving ADCs. 

0.5
07/25/2024

Julie LaBarbera, MSN, RN, AGACNP-BC

Julie LaBarbera, MSN, RN, AGACNP-BC

Sonya Reid, MD, MPH

Sonya Reid, MD, MPH

On-Demand
BriefCase
0.5
07/23/2024

ADCs in HR+/HER2- mBC: Guidelines and Expert Consensus

The second episode of this CEC BriefCase series further explores the same patient case, demonstrates how to turn emerging therapies into practice changing treatment approaches, and considers when and to whom these therapies should be given and how gaps in guideline-concordant care lead to poorer treatment outcomes. 

0.5
07/23/2024

Sara Tolaney, MD, MPH

Sara Tolaney, MD, MPH

On-Demand
BriefCase
0.5
07/23/2024

ADCs in HR+/HER2- mBC: Clinical Trial and Real-world Data

The first episode of this CEC BriefCase series introduces a patient case that demonstrates real-world challenges faced by oncologists and their teams, provides insights into the latest developments in this therapeutic space, and discusses how to consider swiftly developing data as a key component of personalized treatment plans.

0.5
07/23/2024

Sara Tolaney, MD, MPH

Sara Tolaney, MD, MPH